This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

clobazam (Perizam®)

Reference No. 3070

Publication date:

Appraisal information

clobazam (Perizam®) 1 mg/ml oral suspension
clobazam (Perizam®) 2 mg/ml oral suspension

Company: Rosemont Pharmaceuticals Ltd
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 29/04/2016

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, clobazam (Perizam®) cannot be endorsed for use within NHS Wales as an adjunctive therapy in epilepsy in children aged between 2 years and 6 years old, if standard treatment with one or more anticonvulsants has failed: treatment of simple or complex partial epilepsy with or without secondary generalisation and treatment of all types of generalised epilepsy (tonic/clonic, myoclonic, absence seizures).
Statement of Advice (SOA)